Solid Biosciences (SLDB) Non Operating Investment Income (2025 - 2026)

Solid Biosciences' (SLDB) quarterly Non Operating Investment Income came in at -$1.6 million in Q1 2026, little changed year-on-year from -$1.6 million in Q1 2025, and up 37.74% quarter-over-quarter from -$2.6 million in Q4 2025.

Solid Biosciences (SLDB) Non Operating Investment Income (2025 - 2026) Analysis & Trends

Solid Biosciences has disclosed Non Operating Investment Income across 2 years of filings, most recently posting -$1.6 million for Q1 2026.

  • Non Operating Investment Income for Q1 2026 came in at -$1.6 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.0 million (changed N/A YoY), and the FY2025 annual result was -$6.0 million, down 27.37% from the prior year.
  • Non Operating Investment Income came in at -$1.6 million for Q1 2026 at Solid Biosciences, up from -$2.6 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of -$850000.0 in Q3 2025 to a low of -$2.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 235,807.00
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - 230,000.00
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Solid Biosciences 789.54 Mn 408.86 Mn - -1.65 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.65 Mn
Mar 31, 2026 -1.65 Mn
Dec 31, 2025 -2.65 Mn
Dec 31, 2025 -2.65 Mn
Sep 30, 2025 -850,000.00
Sep 30, 2025 -850,000.00
Jun 30, 2025 -900,000.00
Jun 30, 2025 -900,000.00
Mar 31, 2025 -1.65 Mn
Mar 31, 2025 -1.65 Mn